journal
https://read.qxmd.com/read/36906941/chemotherapeutic-drugs-elicit-stemness-and-metabolic-alteration-to-mediate-acquired-drug-resistant-phenotype-in-acute-myeloid-leukemia-cell-lines
#1
JOURNAL ARTICLE
Raveen Stephen Stallon Illangeswaran, Daniel Zechariah Paul Jebanesan, Kezia Kanimozhi Sivakumar, Rakhi Thalayattu Vidhyadharan, Bharathi M Rajamani, Nancy Beryl Janet, Ernest David, Shaji Ramachandran Velayudhan, Vikram Mathews, Poonkuzhali Balasubramanian
Chemotherapy resistance leading to disease relapse is a significant barrier in treating acute myeloid leukemia (AML). Metabolic adaptations have been shown to contribute to therapy resistance. However, little is known about whether specific therapies cause specific metabolic changes. We established cytarabine-resistant (AraC-R) and Arsenic trioxide-resistant (ATO-R) AML cell lines, displaying distinct cell surface expression and cytogenetic abnormalities. Transcriptomic analysis revealed a significant difference in the expression profiles of ATO-R and AraC-R cells...
March 3, 2023: Leukemia Research
https://read.qxmd.com/read/36906942/the-role-of-splenectomy-in-management-of-splenic-b-cell-lymphomas
#2
JOURNAL ARTICLE
William J Archibald, Andrea M Baran, AnnaLynn M Williams, Rabih M Salloum, W Richard Burack, Andrew G Evans, Chauncey R Syposs, Clive S Zent
INTRODUCTION: Splenic B-cell lymphomas are rare and understudied entities. Splenectomy is frequently required for specific pathological diagnosis in patients with splenic B-cell lymphomas other than classical hairy cell leukemia (cHCL), and can be effective and durable therapy. Our study investigated the diagnostic and therapeutic role of splenectomy for non-cHCL indolent splenic B-cell lymphomas. METHODS: Observational study of patients with non-cHCL splenic B-cell lymphoma undergoing splenectomy between 1 August 2011 and 1 August 2021 at the University of Rochester Medical Center...
March 2, 2023: Leukemia Research
https://read.qxmd.com/read/36893697/comparison-of-maintenance-regimens-in-acute-promyelocytic-leukemia-patients
#3
JOURNAL ARTICLE
Ebru Kilic Gunes, Zubeyde Nur Ozkurt, Seyma Yildiz, Gulsum Ozet, Funda Ceran, Murat Albayrak, Merih Reis Aras, Tuba Bulduk, Selim Sayin, Meltem Ayli
Maintenance therapy in APL is still a standard especially in high-risk patients treated with chemotherapy+ATRA combination whereas the role of the maintenance therapy in low-risk patients is controversial. This study aims to compare the efficacy and toxicity of ATRA monotherapy and ATRA+MTX+ 6-MP combination as the maintenance treatment for 2 years in APL patients who achieved molecular complete response after induction and consolidation with ATRA+chemotherapy. A total of 71 patients from 4 different centers were included in this study...
March 2, 2023: Leukemia Research
https://read.qxmd.com/read/36857875/determinants-of-refined-gvhd-free-relapse-free-survival-after-reduced-intensity-allogeneic-hematopoietic-cell-transplantation-in-older-patients-with-myeloid-malignancies
#4
JOURNAL ARTICLE
Pavel Jindra, Michal Karas, Daniel Lysák, Jiří Šrámek, Kateřina Steinerová, Marcela Hrabětová, Alexandra Jungová
BACKGROUND: Older patients with AML/MDS have a poor prognosis with alloHCT as the only curative option. However alloHCT is challenging given its high TRM. Recently, a composite endpoint of GRFS was proposed to define transplant success. A single centre retrospective analysis was performed to determine the main variables influencing GRFS. PATIENTS AND METHODSMETHODS: 91 consecutive patients≥ 60 years (median 64 years, range 60-74) with AML/MDS who received reduced-intensity alloHCT during 2001-2017 analysed...
February 24, 2023: Leukemia Research
https://read.qxmd.com/read/36801700/phf6-mutations-in-myelodysplastic-syndromes-chronic-myelomonocytic-leukemia-and-acute-myeloid-leukemia
#5
LETTER
Alex Bataller, Kelly S Chien, Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Samuel Urrutia, Emmanuel Almanza-Huante, Georgina Gener-Ricos, Farhad Ravandi, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero
No abstract text is available yet for this article.
February 15, 2023: Leukemia Research
https://read.qxmd.com/read/36801588/incidence-and-predisposing-factors-of-infection-in-patients-treated-with-hypomethylating-agents
#6
JOURNAL ARTICLE
Tugcan Alp Kirkizlar, Onur Kirkizlar, Ufuk Demirci, Aytug Umut, Huseyin Iflazoglu, Elif Gulsum Umit, Ahmet Muzaffer Demir
OBJECTIVE: Hypomethylating agents may have adverse effects such as cytopenias, cytopenia associated infections and fatality due to infections despite their favorable effects in the treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The infection prophylaxis approach is based on expert opinions and real-life experiences. Hence, we aimed to reveal the frequence of infections, predisposing factors of infection and to analyse infection attributable mortality in patients with high-risk MDS, CMML and AML who received hypomethylating agents in our center where routine infection prophylaxis is not applied...
February 15, 2023: Leukemia Research
https://read.qxmd.com/read/36812661/incidence-of-second-primary-malignancies-in-relapsed-refractory-b-cell-non-hodgkin-s-lymphoma-patients-in-england
#7
JOURNAL ARTICLE
Montserrat Miret, Amanda Anderson, Pooja Hindocha, Lorena Cirneanu, Christina Lymperopoulou, Emanuil Markov, William Kizito, Ferdinando Emanuele Vegni
BACKGROUND: Treatments for relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) may be associated with an increased risk of second primary malignancies (SPMs). Currently available SPM incidence benchmarks are unreliable due to small sample sizes. METHODS: The Cancer Analysis System (CAS), a population-level cancer database in England, was used to identify patients with incident B-cell NHL diagnosed during 2013-2018 with evidence of r/r disease. Incidence rates (IRs) of SPMs after r/r disease diagnosis were calculated per 1000 person-years (PYs) and stratified by age, sex, and SPM type...
February 14, 2023: Leukemia Research
https://read.qxmd.com/read/36801702/comparison-between-azacitidine-and-decitabine-as-front-line-therapy-in-elderly-acute-myeloid-leukemia-patients-not-eligible-for-intensive-chemotherapy
#8
JOURNAL ARTICLE
L Maurillo, A Spagnoli, A Candoni, C Papayannidis, E Borlenghi, D Lazzarotto, L Fianchi, M Sciumè, M E Zannier, F Buccisano, M I Del Principe, V Mancini, M Breccia, R Fanin, E Todisco, M Lunghi, R Palmieri, N Fracchiolla, P Musto, G Rossi, A Venditti
We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients with untreated AML, diagnosed according to WHO criteria. In the two groups, we evaluated complete remission (CR), overall survival (OS) and disease free survival (DFS). The AZA and DEC groups included 139 and 186 patients, respectively. To minimize the effects of treatment selection bias, adjustments were made using the propensity-score matching method, which yielded 136 patient pairs. In the AZA and DEC cohort, median age was 75 years in both, (IQR, 71-78 and 71-77), median WBCc at treatment onset 2...
February 14, 2023: Leukemia Research
https://read.qxmd.com/read/36801701/recombinant-human-p53-adenovirus-injection-combined-with-bortezomib-inhibits-proliferation-and-promotes-apoptosis-in-multiple-myeloma
#9
JOURNAL ARTICLE
Qiangsheng Wang, Qiqin Shi, Yingchao Chen, Gang Wang, Lijing Shen
BACKGROUND: Multiple myeloma (MM) is a B-cell malignancy characterized by abnormal proliferation of clonal plasma cells in the bone marrow, the incidence of which has further increased in recent years. In multiple myeloma, wild-type functional p53 is often inactivated or dysregulated. Therefore, this study aimed to investigate the role of p53 knockdown or overexpression in multiple myeloma and the therapeutic effect of recombinant adenovirus-p53 (rAd-p53) in combination with Bortezomib...
February 14, 2023: Leukemia Research
https://read.qxmd.com/read/36812660/tyrosine-kinase-inhibitors-combined-with-venetoclax-and-azacytidine-as-an-effective-therapy-for-de-novo-lymphoid-blast-phase-chronic-myeloid-leukemia
#10
LETTER
Zhihuan Yang, Chunhua Liu, Yimin Hu, Hong Liu, Junfan Li, Lihua Wu, Qingguo Liu, Yali Zheng, Pingping Huang, Ying Wang
No abstract text is available yet for this article.
February 12, 2023: Leukemia Research
https://read.qxmd.com/read/36841022/from-bone-marrow-failure-syndromes-to-vexas-disentangling-clonal-hematopoiesis-immune-system-and-molecular-drivers
#11
JOURNAL ARTICLE
Carmelo Gurnari, Valeria Visconte
Clonal hematopoiesis (CH) is a result of the selective expansion of hematopoietic stem and progenitor cells (HSPCs) carrying somatic mutations originating from a primary HSC. The advent of modern genomic technologies has helped recognizing that CH is common in elderly healthy subjects as a result of the aging bone marrow (BM). CH in healthy subjects without abnormalities in blood counts is known as CH of indeterminate potential. CH is also seen in BM failure (BMF) disorders. Whether CH alarms for the risk to develop malignant evolution in BMF or creates an adaptation to selective pressure is a matter of controversy...
February 11, 2023: Leukemia Research
https://read.qxmd.com/read/36801522/evaluation-of-the-simplified-score-to-predict-early-relapse-in-multiple-myeloma-s-ermm-in-the-mmrf-commpass-study
#12
JOURNAL ARTICLE
Michael Slade, Mark Fiala, Sarah Kelley, Zachary D Crees, Mark A Schroeder, Keith Stockerl-Goldstein, Ravi Vij
BACKGROUND: Zaccaria and colleagues recently proposed a new risk score to identify patients at high risk for relapse within 18 months of diagnosis (ER18), the Score for Early Relapse in Multiple Myeloma (S-ERMM). We performed external validation of the S-ERMM using data from the CoMMpass study. PATIENTS AND METHODS: Clinical data was obtained from the CoMMpass study. Patients were assigned S-ERMM risk scores and risk categories by the three iterations of the International Staging System (ISS): ISS, R-ISS and R2-ISS...
February 11, 2023: Leukemia Research
https://read.qxmd.com/read/36906940/differential-effects-of-recombinant-human-thrombopoietin-on-clinical-outcomes-in-cd7-positive-and-cd7-negative-acute-myeloid-leukaemia
#13
JOURNAL ARTICLE
Xiaobai Sun, Yanliang Bai, Mengyi Li, Weiya Li, Haoyan Wang, Mengyu Xiao, Liurui Dou, Juanjuan Song, Junwei Niu, Xingjun Xiao, Yuqing Chen, Kai Sun
To investigate the effect of recombinant human thrombopoietin (rhTPO) application on the clinical outcomes of CD7-positive acute myeloid leukaemia (CD7 + AML) patients following chemotherapy, we retrospectively studied 159 newly diagnosed non-M3 AML patients. Patients were divided into the following four groups according to the expression of CD7 in AML blasts and the use of rhTPO after chemotherapy: the CD7 + rhTPO group (n = 41), the CD7 + non-rhTPO group (n = 42), the CD7 negative (CD7-) rhTPO group (n = 37), and the CD7- non-rhTPO group (n = 39)...
February 8, 2023: Leukemia Research
https://read.qxmd.com/read/36774789/clinicopathologic-characteristics-of-myeloproliferative-neoplasms-with-jak2-exon-12-mutation
#14
JOURNAL ARTICLE
Kran Suknuntha, Julia T Geyer, Keyur Pravinchandra Patel, Olga K Weinberg, Heesun J Rogers, Jonathan I Lake, Luke Lauridsen, Jay L Patel, Michael J Kluk, Daniel A Arber, Eric D Hsi, Adam Bagg, Carlos Bueso-Ramos, Attilio Orazi
The presence of JAK2 exon 12 mutation was included by the 2016 World Health Organization (WHO) Classification as one of the major criteria for diagnosing polycythemia vera (PV). Few studies have evaluated the clinical presentation and bone marrow morphology of these patients and it is unclear if these patients fulfill the newly published criteria of 5th edition WHO or The International Consensus Classification (ICC) criteria for PV. Forty-three patients with JAK2 exon 12 mutations were identified from the files of 7 large academic institutions...
February 8, 2023: Leukemia Research
https://read.qxmd.com/read/36773488/late-appearance-of-jak2-mutated-polycythaemia-vera-in-a-patient-with-typical-chronic-myeloid-leukaemia-on-imatinib-speculations-about-role-of-therapeutic-pressure-and-of-secondary-genetic-events
#15
LETTER
Gianfranco Lapietra, Maria Zaira Limongi, Sonia Buffolino, Mauro Nanni, Daniele Ballarò, Maurizio Martelli, Marco Mancini
No abstract text is available yet for this article.
February 8, 2023: Leukemia Research
https://read.qxmd.com/read/36764024/bcr-abl-is-enriched-in-s-and-g-2-cell-cycle-phases
#16
LETTER
Bradley A Nicholas, Reshma Purohit, Andrew D Woods, Kavya Kannan, Ganapati Srinivasa, Julia A Bridge, Jin-Ah Kim, Charles Keller
No abstract text is available yet for this article.
February 8, 2023: Leukemia Research
https://read.qxmd.com/read/36758375/spectrum-of-second-primary-malignancies-and-cause-specific-mortality-in-pediatric-and-adult-langerhans-cell-histiocytosis
#17
JOURNAL ARTICLE
Gaurav Goyal, Richa Parikh, Joshua Richman, Jithma P Abeykoon, Diana Morlote, Ronald S Go, Smita Bhatia
With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a growing survivor population that might be at risk for late mortality from non-LCH causes, including second primary malignancies (SPMs). We undertook a large study using the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the patterns of SPMs and cause-specific mortality among individuals with LCH (2000-2016) from the US. We found an increased risk of SPMs in the cohort (standardized incidence ratio [SIR] 2...
February 6, 2023: Leukemia Research
https://read.qxmd.com/read/36822077/clonal-hematopoiesis-onset-in-chronic-myeloid-leukemia-patients-developing-an-adverse-cardiovascular-event
#18
JOURNAL ARTICLE
Francesco Tarantini, Cosimo Cumbo, Antonella Zagaria, Luisa Anelli, Elisa Parciante, Immacolata Redavid, Nicoletta Coccaro, Giuseppina Tota, Maria Rosa Conserva, Crescenzio Francesco Minervini, Angela Minervini, Immacolata Attolico, Antonella Russo Rossi, Giorgina Specchia, Pellegrino Musto, Francesco Albano
Life expectation of chronic myeloid leukemia patients in the tyrosine kinase inhibitors era is almost equal to that of healthy subjects. On the other hand, their long-term management must take into account a higher risk of adverse events, at least partly related to the treatment. Various studies reported a higher incidence of cardiovascular events in these patients. Clonal hematopoiesis is broadly considered a major independent risk factor for cardiovascular events. Of note, the underlying physiopathological mechanisms connect clonal hematopoiesis with a global proinflammatory status, triggering a vicious circle in which the somatic mutations and inflammation feed each other...
January 24, 2023: Leukemia Research
https://read.qxmd.com/read/36696828/association-of-abcb1-abcg2-drug-transporter-polymorphisms-and-smoking-with-disease-risk-and-cytogenetic-response-to-imatinib-in-chronic-myeloid-leukemia-patients
#19
JOURNAL ARTICLE
Fatemeh Mohammadi, Golale Rostami, Mohammad Hamid, Mohammad Shafiei, Masoumeh Azizi, Hasan Bahmani
BACKGROUND: Despite acceptable results of imatinib in the treatment of chronic myeloid leukemia (CML), some patients fail to acquire a complete cytogenetic response (CCyR), which may be caused by polymorphisms in the pharmacogenetic genes. The study aimed to evaluate the association of two polymorphisms in the ABCB1 and ABCG2 genes with cytogenetic response to imatinib and the risk of CML development. METHODS: We genotyped ABCB1 (c .2677G/T/A) and ABCG2 (c .421C/A) polymorphisms by PCR-RFLP, T-ARMS-PCR methods in 111 patients with CML and 102 sex- and age-matched healthy subjects...
January 21, 2023: Leukemia Research
https://read.qxmd.com/read/36696829/therapy-selected-clonal-hematopoiesis-and-its-role-in-myeloid-neoplasms
#20
JOURNAL ARTICLE
Jacob Jahn, Benjamin Diamond, Jeffrey Hsu, Skye Montoya, Tulasigeri M Totiger, Ola Landgren, Francesco Maura, Justin Taylor
Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and mutational signatures...
January 20, 2023: Leukemia Research
journal
journal
27133
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.